Aclarion Announces First Commercial Agreement in Michigan
14 8월 2024 - 9:08PM
Aclarion, Inc.,
(“Aclarion” or the “Company”) (Nasdaq:
ACON, ACONW), a healthcare technology company that is
leveraging biomarkers and proprietary augmented intelligence
algorithms to help physicians identify the location of chronic low
back pain, announced today it has established a commercial
agreement with Sheridan Community Hospital in Sheridan, Michigan.
The agreement brings Nociscan to central Michigan and leading
neurosurgeon, John Keller, MD.
“As I work through how to best treat my patients, I’m excited to
work with Sheridan Hospital and Nociscan to continue to develop
safe, noninvasive, and cost-effective tools to help in the precise
identification of disc pain,” said John Keller, MD, Neurosurgeon.
“Building upon the evidence that is already mounting in favor of
using MR spectroscopy and Nociscan is important work that I’m
enthusiastic to undertake.”
Chronic low back pain (cLBP) is a global healthcare problem with
approximately 266 million people worldwide suffering from
degenerative spine disease and low back pain. Aclarion’s Nociscan
solution is the first evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Nociscan objectively
quantifies chemical biomarkers demonstrated to be associated with
disc pain. When used with other diagnostic tools, Nociscan provides
critical insights into the location of a patient’s low back
pain.
“At Sheridan Community Hospital, we are committed to bringing
dedication and expertise to provide individual-based professional
health care for the families in our community – and beyond,” says
Lili Petricevic, CEO of Sheridan Community Hospital. “We are
thrilled to engage with Aclarion and bring their innovative
solution, Nociscan, to our community. Low back pain affects
our community and Nociscan will be a valuable decision support tool
when choosing treatment options.”
Aclarion has recently announced insurance coverage in the UK
from leading insurers. Introducing Nociscan in markets like
Sheridan continues the progression of providing access as a step on
the path to payer coverage in the US.
For more information about Sheridan Hospital, please visit:
https://www.sheridanhospital.com
For more information about Dr. Keller, please visit:
https://greatlakesneuro.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies.
For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company’s current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
“anticipates,” “believes” and “expects” or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company’s current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024